India markets closed

Agenus Inc. (AGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.18-0.12 (-2.26%)
As of 1:39PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.30
Open5.30
Bid5.18 x 1300
Ask5.19 x 1100
Day's range5.10 - 5.36
52-week range2.50 - 5.95
Volume2,260,475
Avg. volume5,317,737
Market cap1.152B
Beta (5Y monthly)1.35
PE ratio (TTM)N/A
EPS (TTM)-1.02
Earnings date04-Aug-2021 - 09-Aug-2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.50
  • Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
    GlobeNewswire

    Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference

    LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will present at the Raymond James 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 from 8:40 a.m. to 9:10 a.m. ET. The presentation will be webcast live

  • Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
    GlobeNewswire

    Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

    LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, for the treatment of recurrent or metastatic cervica

  • Agenus Announces Virtual Annual Shareholders Meeting
    GlobeNewswire

    Agenus Announces Virtual Annual Shareholders Meeting

    LEXINGTON, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that its annual meeting will begin at 5:00 p.m. ET on June 15, 2021 and will be conducted in a virtual format only. Registration for attendees will start at 4:45 p.m. ET. To participate in the Annual Shareholders Meeting, sha